Professor Stephen Worthley
MBBS, PhD, FRACP, FACC, FRCP, FCSANZ, FAICD
Interventional Cardiology
Professor Stephen Worthley is a highly respected cardiologist known for his pioneering work in cardiovascular medicine and clinical research. With a career spanning decades, he’s helped advance minimally invasive treatments and improve patient outcomes worldwide. Despite his international reputation, he remains approachable, deeply committed to teaching, and focused on delivering compassionate, evidence-based care to his patients.
In Sydney, he performs all interventional procedures at Macquarie University Hospital and consults with patients at his rooms in Chatswood and the Mater Hospital (North Sydney). In Wagga Wagga, he performs coronary procedures at Wagga Wagga Base Hospital and Calvary Riverina Hospital, and consults at Riverina Cardiology.
Chatswood Heart
Suite 901, Level 9, South Tower
1–5 Railway Street
Chatswood NSW 2067
TEL: 02 9411 3930
email@macquarieheart.com.au
Cardiology at the Mater
Suite 1.11, Mater Clinic
3–9 Gillies Street
North Sydney NSW 2060
TEL: 02 8904 9301
admin@catm.net.au
Riverina Cardiology
20 Docker Street
Wagga Wagga NSW 2650
TEL: 02 6926 0300
admin@riverinacardiology.com.au
Services
Professor Worthley offers a comprehensive range of consulting, echo/stress echo and interventional cardiology services, combining advanced expertise with a patient-centred approach. His work spans preventive care, diagnostic evaluation, and leading-edge cardiovascular procedures tailored to each individual’s needs.
-
Professor Worthley is available to see all patients. His particular expertise lies in the management of coronary artery disease and valvular heart disease..
-
An ultrasound-based imaging modality providing real-time assessment of cardiac structure and function. It evaluates chamber size, wall motion, valvular morphology, and blood flow patterns.
-
Combines echocardiography with exercise induced stress. It detects flow-limiting coronary disease by revealing wall motion abnormalities not evident at rest.
-
ItAn invasive diagnostic test in which a catheter is advanced to the coronary arteries and contrast dye is injected. X-ray imaging outlines the presence, location, and severity of coronary artery disease.em description
-
A percutaneous procedure used to restore blood flow in narrowed or blocked coronary arteries. It typically involves balloon angioplasty and stent implantation, sometimes supported by adjunctive techniques such as atherectomy (plaque removal) or intracoronary imaging (IVUS/OCT) for optimization.
-
A catheter-based procedure to seal the left atrial appendage, a common site of thrombus formation in atrial fibrillation. It reduces stroke risk in patients unsuitable for long-term anticoagulation.
-
Structural heart interventions performed via catheter to close abnormal communications between the atria. Devices are deployed to reduce right-to-left shunting and associated risks such as paradoxical embolism or right heart strain.
-
A minimally invasive alternative to surgical aortic valve replacement predominantly for severe aortic stenosis. A bioprosthetic valve is implanted via catheter (commonly transfemoral) to relieve obstruction and improve hemodynamics.
-
A catheter-delivered bioprosthetic valve replacement for patients with severe mitral valve disease who are high-risk for open surgery. It restores valve function and improves symptoms of heart failure.
Prof. Stephen Worthley graduated from Medicine at the Adelaide University, South Australia. His training included his Cardiology fellowship at the Royal Adelaide Hospital, his PhD at the Mount Sinai Medical Centre in New York, and post-doctoral research and interventional fellowship at Monash Medical Centre, Melbourne. He established the first dedicated Cardiac CT and MR units in the Asia Pacific region, as well as leading the Cardiovascular Research Centre at the University of Adelaide as the Helpman Professor of Cardiovascular Medicine, a position he held between 2004 to 2016.
He has published over 250 manuscripts, 5 book chapters, and co-edited a Cardiovascular Textbook. He leads a number of novel international multi-centre cardiovascular therapy trials, and his clinical and research expertise spans natriuretic peptide and stem cell therapies though to transcatheter valve implantation and renal artery denervation therapy. He sits on numerous industry advisory boards, journal editorial boards and government advisory groups.
In 2002 he initiated a radial artery access program at the Royal Adelaide Hospital, which rapidly evolved to become the largest volume radial access program in Australia. He is internationally renowned for his interventional and imaging academic work. He has actively trained and educated fellow Cardiologists in interventional therapies around the world, including a sabbatical in 2014 when he moved to Brussels to proctor TAVR procedures throughout Europe and North America.
In 2016 Steve became Chief Medical Officer at GenesisCare and established a national research network. Less than a year later he accepted the role of Executive Manager HeartCare and Sleepcare which saw him lead a network of over 80 Cardiologists across 6 Practices located in all mainland states of Australia. In November 2020 his remit increased to span the Integrated Cancer Care program and bring a coordinated, quality approach to the clinical care of patients with Cancer. With the completion of the North Shore Health Hub Integrated Cancer Centre, the largest single centre of it's type in Australia in August 2021, he moved on from GenesisCare to continue his focus on Cardiovascular Device innovation and clinical practice in Sydney, Australia. He has a base at Macquarie University Hospital where he holds his academic appointment and performs his clinical structural interventional work. He is also the Executive Chairman of Three Peaks Medical, a medical device company focussed on innovation in the delivery of large bore medical devices and therapies.
About Professor Worthley
Fellow
Cardiac Society of Australia and New Zealand,
Fellow
Royal Australasian College of Physicians
Fellow
Royal College of Physicians (UK)
Fellow
American College of Cardiology
PhD Medicine
Mount Sinai School of Medicine, New York
Bachelor of Medicine, Bachelor of Surgery -MBSS, Medicine
University of Adelaide
Credentials/Accreditations
Professor Worthley has authored more than 250 peer-reviewed publications spanning the spectrum of cardiovascular medicine — from high-resolution cardiac imaging with MRI and CT to the development and evaluation of novel coronary interventional devices, transcatheter aortic valve implantation (TAVI) platforms, and emerging mitral valve therapies. The following are some interviews and presentations and five of his most influential and clinically significant papers from recent years.
Publications and Presentations
First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study
Worthley SG, Abizaid A, Kirtane AJ, Simon DI, Meredith IT, Sinnaeve PR, et al
JACC: Cardiovascular Interventions. 2017;10(2):147-156. doi:10.1016/j.jcin.2016.10.020Transcatheter reshaping of the mitral annulus in patients with functional mitral regurgitation: one-year outcomes of the MAVERIC trial.
Worthley S, Redwood S, Hildick-Smith D, Rafter T, Whelan A, De Marco F, Horrigan M, Delacroix S, Gregson J, Erglis A.
EuroIntervention. 2021;16(13):1106-1113. doi:10.4244/EIJ-D-20-00484.1-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: The HighLife TSMVR Feasibility Study
Schneider LM, Worthley S, Nickenig G, Huczek Z, Wojakowski W, Tchetche D, Dubois C, Nasr M, Verhees L, Rothman M, Piazza N, Buithieu J, Yeow WL, Kessler M, Rottbauer W.
JACC: Cardiovascular Interventions. 2023;16(23):2854-2865. doi:10.1016/j.jcin.2023.09.003.Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study.
Søndergaard L, Walton AS, Worthley SG, Smith D, Chehab B, Manoharan G, Yong G, Bedogni F, Bates N, Reardon MJ.
EuroIntervention. 2023;19(3):248-255. doi:10.4244/EIJ-D-22-01108.Thirty-Day and 1-Year Outcomes of Navitor Transcatheter Aortic Valve in Low- or Intermediate-Risk Patients.
Worthley SG, Giordano A, Corcione N, Nombela-Franco L, De Marco F, Walton A, Bedogni F, Möllmann H, De Backer O, Leroux L, Manoharan G, Tchétché D, Taramasso M, Li L, Kuo H-C, Van Mieghem NM; VANTAGE study investigators
JACC: Cardiovascular Interventions. 2025; Epub ahead of print (Aug 21, 2025). doi:10.1016/j.jcin.2025.08.021.
Contact Professor Worthley
Chatswood Heart
Suite 901, Level 9, South Tower
1–5 Railway Street
Chatswood NSW 2067
TEL: 02 9411 3930
email@macquarieheart.com.au
Cardiology at the Mater
Suite 1.11, Mater Clinic
3–9 Gillies Street
North Sydney NSW 2060
TEL: 02 8904 9301
admin@catm.net.au
Riverina Cardiology
20 Docker Street
Wagga Wagga NSW 2650
TEL: 02 6926 0300
admin@riverinacardiology.com.au